Core Viewpoint - Roche Holding's CEO Thomas Schinecker announced discussions with the U.S. government regarding direct-to-patient sales, aiming to significantly reduce costs and eliminate profit-driven intermediaries [1] Group 1: Company Strategy - The company is exploring a direct sales model to patients, which is expected to lower costs "quite quickly" [1] - Schinecker emphasized the need to remove entities that prioritize profit over patient care [1] Group 2: Product Example - The multiple sclerosis drug Ocrevus was cited as an example, where even with lower pricing compared to competitors, additional fees are still imposed [1]